In this context, the class I HDAC inhibitor mocetinostat was recently shown to inhibit the expression of ZEB1, to upregulate its target, miR‐203, and to restore sensitivity to chemotherapy in pancreatic cancer cells (Meidhof et al, 2015). This evidence concerns the gene HDAC9 and pancreatic neoplasm.